Patents Examined by Samira J Jean-Louis
  • Analogs of proxisome proliferator activated receptor (PPAR) agonists and methods of using the same
    Patent number: 10776461
    Abstract: Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: September 15, 2020
    Assignee: The University of Toledo
    Inventors: Bruce E. Heck, Dong Hyun Kim, Paul W. Erhardt, Brian J. Kress
  • Therapeutic drug for dyskinesia
    Patent number: 10758535
    Abstract: The present invention provides a therapeutic drug that is useful for levodopa induced dyskinesia in Parkinson's disease. In particular, the present invention provides a composition and method for treating, improving, suppressing the progression, or preventing motor complications associated with levodopa therapy for Parkinson's disease, especially levodopa induced dyskinesia (PD-LID), comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or a pharmaceutically acceptable salt or prodrug thereof is parenterally administered.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: September 1, 2020
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Mitsumasa Kurita, Yuki Ikeda, Mitsuhiro Nakato
  • Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer
    Patent number: 10758541
    Abstract: This application relates to methods of treating and/or preventing cancer (e.g., non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma) in patients in need thereof comprising administering to the patient a therapeutically effective amount of a CDK inhibitor (e.g., milciclib) in combination with a therapeutically effective amount of another anticancer drug (e.g., sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib).
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: September 1, 2020
    Assignee: Tiziana Life Sciences PLC
    Inventor: Kunwar Shailubhai
  • Polymorphic form of N-{6-(hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
    Patent number: 10759758
    Abstract: The present invention relates to crystalline forms of N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide, to processes for their preparation, to pharmaceutical compositions comprising them and to their use in the control of disorders.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: September 1, 2020
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Tobias Thaler, Johannes Platzek, Nicolas Guimond
  • Compositions and kits for omeprazole suspension
    Patent number: 10751333
    Abstract: Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: August 25, 2020
    Assignee: CUTISPHARMA, INC.
    Inventors: Zeus Pendon, Steven Dinh
  • Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
    Patent number: 10730879
    Abstract: Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: August 4, 2020
    Assignee: Gilead Calistoga LLC
    Inventors: Ernest Carra, Michael Gerber, Bing Shi, Keiko Sujino, Duong Tran, Fang Wang, Jerry B. Evarts
  • Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
    Patent number: 10722478
    Abstract: The present invention relates to methods for the treatment or prevention of fatigue associated with disordered sleep, for example, in multiple sclerosis, fibromyalgia, Fabry's disease, Parkinson's disease, or traumatic brain injury, using cyclobenzaprine. The present invention further relates to a biomarker for the therapeutic effects of a cyclobenzaprine treatment.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: July 28, 2020
    Assignee: Tonix Pharma Holdings Limited
    Inventors: Seth Lederman, Herb Harris
  • Hest G-18-0 and benzoyl peroxide compositions and methods for using the same
    Patent number: 10722488
    Abstract: The compositions of the various embodiments include benzoyl peroxide and Hest G-18-0. The methods of this invention include treating acne, increasing the solubility of benzoyl peroxide, and treating the skin. Embodiments are also directed to a dual chamber package comprising a chamber for benzoyl peroxide and a chamber for Hest G-18-0.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: July 28, 2020
    Assignee: RODAN & FIELDS, LLC
    Inventors: Kathy Ann Fields, Kathryn Pregerson Rodan, George Paul Majewski, Timothy John Falla, Dzung Q. Le
  • Chemical compounds
    Patent number: 10717746
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: July 21, 2020
    Assignee: ASTRAZENECA AB
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
    Patent number: 10716774
    Abstract: Isotretinoin compositions having improved bioavailability are disclosed. The compositions are oral formulations containing isotretinoin, a lipid excipient and a cosolvent, wherein the ratio of isotretinoin to the lipid excipient is from about 1:1.2 to about 1:1.6. The compositions can be in the form of a pharmaceutically acceptable oral dosage form such as a capsule or compressed tablet wherein the isotretinoin is adsorbed onto blended particles of a cellulosic polymer and silicon dioxide in combination with a lipid excipient such as soy phosphatidylcholine and a cosolvent such as propylene glycol. Methods of preparing the compositions and methods of treatment using the compositions are also disclosed.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: July 21, 2020
    Assignee: YALE PHARMACEUTICALS LLC
    Inventor: Basavaraj Siddalingappa
  • Therapeutically active compounds and their methods of use
    Patent number: 10717764
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: July 21, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Janeta Popovici-Muller, Rene M. Lemieux, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
  • Highly active anti-neoplastic and anti-proliferative agents
    Patent number: 10709711
    Abstract: This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: July 14, 2020
    Assignee: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • Devices and methods of treating methamphetamine addiction and medical and behavioral consequences of methamphetamine use and of HIV infection
    Patent number: 10702537
    Abstract: A method of treating a condition of in a human patient comprising pharmacologically activating a translocator protein of 18 kDa (TSPO), wherein the condition is one of a chronic methamphetamine addiction, a medical consequence of methamphetamine use; a behavioral consequence of methamphetamine use, an HIV associated cognitive motor disorder, an HIV-associated neurodegenerative disorder, and a neuroinflammatory response.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: July 7, 2020
    Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY and Agricultural and Mechanical College
    Inventors: Nicholas E. Goeders, Christopher Dalton Schmoutz
  • Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity
    Patent number: 10696652
    Abstract: A method of treating a mammal suffering from a cancer responsive to inhibition of protein kinase activity, by administering to the mammal an amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, effective to inhibit protein kinase activity, wherein the compound of formula (I) is:
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: June 30, 2020
    Assignee: Vernalis (R&D) Ltd.
    Inventors: Stephen Stokes, Nicolas Foloppe, Andrea Fiumana, Martin Drysdale, Simon Bedford, Paul Webb
  • Methods, compositions, and uses of novel Fyn kinase inhibitors
    Patent number: 10688093
    Abstract: The present invention provides methods for inhibiting Fyn kinase, using 5-3-pyridin-2-amine, 6-3-imidazo[1,2-a] pyrazine, 6-3-imidazo[1,2-b] pyridazine, N-(5-imidazo [2,1-b][1,3,4] thiadiazol-2-yl)-amine, 4-3-1H-pyrazolo[3,4-b] pyridine, and N-(3-imidazo [1,2-b] pyridazin-6-yl) amine compounds and methods of treatment, prevention, inhibition or amelioration of diseases and conditions associated with Fyn kinase using such compounds.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: June 23, 2020
    Inventor: Warren C. Lau
  • Heterocyclic compounds and uses thereof
    Patent number: 10675286
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: June 9, 2020
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Jeffery L. Kutok, David G. Winkler, Vito J. Palombella
  • RET inhibitor
    Patent number: 10668075
    Abstract: A compound represented by the following general formula (I) [the symbol in the formula are as defined in the description], a salt thereof, or the like is a RET inhibitor or RET tyrosine kinase inhibitor that can be used as an agent for the prevention or treatment of disorders including cancers and cancer metastasis having mutations in RET.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: June 2, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tatsushi Kodama, Hiroshi Sakamoto, Toshiyuki Tsukaguchi
  • Furostan-3-ol derivatives as skeletal muscle hypertrophic agents
    Patent number: 10662219
    Abstract: Compounds of formula I are disclosed. The compounds are useful for promoting skeletal muscle hypertrophy or treating skeletal muscle atrophy.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: May 26, 2020
    Assignee: EMMYON, INC.
    Inventor: John J Talley
  • Compounds for treatment of cancer
    Patent number: 10660889
    Abstract: The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of cancer.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: May 26, 2020
    Assignee: Curegenix, Inc.
    Inventor: Songzhu An
  • Heteroaryl estrogen receptor modulators and uses thereof
    Patent number: 10654867
    Abstract: Described herein are heteroaryl compounds with estrogen receptor modulation activity or function having the Formula I, II, and III structures: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I, II, and III compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: May 19, 2020
    Assignee: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Li, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Nicholas Charles Ray, Simon Goodacre, Jiangpeng Liao